#ObesityCare #GLP1 #GLP1Medications #PublicHealth #WeightStigma #HealthEquity #ObesityTreatment #PatientSupport #HealthcareAccess #ObesityResearch #PersonCentredCare #HealthInequalities Registered Dietitian | Obesity Care & Health Strategy | Behavioural Science in Digital Health | Behavioural Intervention Design | Clinical Innovation New consensus statement, out this week in The Lancet Diabetes & Endocrinology, from European Association for the Study of Obesity (EASO), The European Federation of the Associations of Dietitians (EFAD) and ECPObesity: "Nutritional, functional, and psychological considerations for incretin-based therapies in adults." Link in comments
van Hulsteijn LT, Pasquali R, Casanueva F, Haluzik M, Ledoux S, Monteiro MP, et al
These drugs might stop that from happening
We do this through: Measured dose titration to minimize side effects Close clinical monitoring to adjust medications as your body changes Preventative strategies to avoid Ozempic face, nutrient deficiencies, and fatigue Personalized medical support throughout your weight loss journey Were proactive, not reactive